견적문의

BURLINGAME, CALIF.--( / )--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced the appointment of Ken Trbovich to the newly-created role of SVP of Investor Relations, effective immediately, reporting to Timothy E. Morris, COO/CFO of Humanigen.

Mr. Trbovich brings to Humanigen 20 years of experience on Wall Street as a Managing Director and Senior Analyst at several leading investment banks including Janney Montgomery Scott, MLV & Co. (now part of B. Riley), C.E. Unterberg, Towbin (now part of Canaccord Genuity), and Royal Bank of Canada. During the course of his career he has analyzed developments at more than 100 companies and produced over 2,000 research reports, and has developed an extensive network of investors, analysts and investment bankers. Ken also has experience working with multiple biopharmaceutical companies at the start-up to commercial stage in a variety of disease indications. He has an MBA from Thunderbird School of International Management, earned a CFA designation, and has held multiple FINRA licenses.

“Humanigen is pleased to welcome Ken,” said Cameron Durrant, CEO of Humanigen. “His background and extensive skills on Wall Street and in the biopharmaceutical space will be instrumental to Humanigen as we progress our pipeline plans.”

“Ken’s work as a covering analyst for two decades and more recently as an entrepreneur brings a unique and valuable skill set,” commented Timothy E. Morris COO/CFO of Humanigen. “We are fortunate to add Ken at this critical time in the company’s growth and look forward to leveraging his network and experience with current and future shareholders.”

Mr. Trbovich will be responsible for interfacing with investors and analysts as a key member of the Humanigen management team as the company prepares for potential distribution of lenzilumab for COVID-19 under Emergency Use Authorization, and as Humanigen expands its pipeline programs.

“I am excited to join Humanigen and utilize my market expertise to help the company continue to advance in the biopharmaceutical field,” says Ken Trbovich. “With Humanigen’s recent submission for Emergency Use Authorization for lenzilumab, the team is working to take Humanigen to the next level for commercialization and I am looking forward to assisting the company at this exciting stage.”

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of inflammation and immuno-oncology. Humanigen’s immediate focus is to prevent or minimize cytokine release syndrome that precedes severe lung dysfunction in hospitalized and hypoxic patients with COVID-19 pneumonia. Humanigen is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) and cytokine release syndrome associated with CAR-T, bispecific, and other T-cell-engaging therapies, eosinophilic asthma, and rheumatoid arthritis. For more information, visit and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements, including, without limitation, statements regarding the potential commercialization and distribution of lenzilumab if emergency use authorization were granted, and other statements regarding Humanigen’s beliefs relating to the technologies in Humanigen’s current pipeline.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in the company’s lack of profitability and potential need for additional capital to grow its business; its dependence on partners to further the development of its product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the “Risk Factors” sections and elsewhere in Humanigen's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. The company undertakes no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

SEOUL--()--Schneider Electric, the leader in 시알리스정10MG the digital transformation of energy management and 콘래드서울 SEOUL--()--Schneider근화동홀덤펍 is supporting the work of the 근화동홀덤펍 테스토스테론주사 International Union for Conservation of Nature (IUCN) to preserve the integrity and diversity of the world’s 네비도효능 natural ecosystems by attending the IUCN World Conservation Congress, taking place from 3-11 September.

The IUCN Congress starting today in Marseille, France, is a key environmental milestone ahead of the United Nations conferences on biodiversity and climate, to be held in Kunming and Glasgow, respectively, in the coming months, and brings together private and public 근화동홀덤펍 도포마취제 sector stakeholders to drive action on today’s most pressing environmental and sustainability 근화동홀덤펍 challenges.

Schneider Electric, which was named the world’s 근화동홀덤펍 싱귤레어 most sustainable corporation by Corporate Knights Global 100 Index in January SophieRose 2021, has long been committed to ensuring Sierra how companies can promote circularity, protect 근화동홀덤펍 biodiversity and fight climate change through interrelated and interdependent actions for a nature-positive future.

Since releasing its first end-to-end biodiversity footprint assessment in 김이브님 2020, by using the Global Biodiversity Score developed by CDC Biodiversite, Schneider Electric is now better equipped to set targets to tackle its direct and indirect impact on biodiversity. Schneider’s 근화동홀덤펍 고두림 Sustainability Essentials 2021-2025 program oversees 근화동홀덤펍 화정님 the global implementation of conservation initiatives, with over 300 Schneider sites recently taking part in activities to restore ecosystems as part of World Environment Day. Also in the UK, 근화동홀덤펍 위야넷야사 Schneider’s Equipment & Transformers Scarborough plant is actively working with the local council and biodiversity experts to assess the feasibility of redeveloping land adjacent to its factory to attract wildlife, enhance local species and create a biodiversity-rich, well-being space for employees. In France, Schneider’s industrial plant in Brittany is working closely with NGOs for employees to get involved and protect local wildlife.

In May 2021, Schneider published its Biodiversity pledge, committing to no net loss of biodiversity across its direct operations by 2030, and recognized by Act4Nature, an alliance of international companies, NGOs, academic bodies, and public institutions. Schneider is also a member of the 근화동홀덤펍 인터넷다빈치 Science-Based Targets Network for Nature, 근화동홀덤펍 인터넷릴천지 actively involved in the implementation of biodiversity strategies and action plans.

“Our sustainability program combines climate actions with nature conservation and circular business initiatives across Schneider’s global operations, through our wider business ecosystem and with a community of expert partners,” 근화동홀덤펍 체리마스터 said Olivier Blum, Schneider Electric’s Chief Strategy and Sustainability Officer. 야동네이버 “This engagement ─ based on science-based targets, research, and leading by example ─ drives change faster.”

Recent initiatives include collaboration with the Ellen 황금성솔루션 MacArthur Foundation, focusing on how circular economies enable businesses to reduce global biodiversity loss and the launch of 수아넷 the 100 Days of Possibility initiative with the Global Footprint Network, to showcase solutions such as 근화동홀덤펍 AV몽 100% renewable power grids, smart homes, and natural resource waste reduction. Schneider Electric signed the European Plastics Pact at its launch in 경품추첨 Recent2020.

Throughout the IUCN Congress, the Schneider Electric Foundation, under 근화동홀덤펍 비뇨기과 the aegis of Fondation de France, will partner with 농구언더오버 Throughoutof Change 21’s exhibition and creative workshops 근화동홀덤펍 조루수술비용 to raise public awareness of the climate emergency. Schneider Electric representatives will also participate 근화동홀덤펍 한방정력제 in round table discussions.Korea Newswire distributes your news 먹는조루약 across every media channels through the industry’s largest press release distribution network